Skip to main content
Fig. 2 | Genome Biology

Fig. 2

From: Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Fig. 2

Characterization of AR mutants identified in patient VC-012 after progression on bicalutamide and enzalutamide. a Two AR mutants were identified in the cfDNA isolated after patient progression on bicalutamide. Both mutants show agonist response to bicalutamide in an in vitro transcription assay. b Four additional mutants were identified in the same patient VC-012 after progression on enzalutamide, all with various agonist effects toward enzalutamide in vitro. The percentage in the charts only reflects the mutated form of the androgen receptor. Each concentration was assayed in quadruplicate n = 4, with a biological replicate of n = 3. Results were averaged and normalized by expressing them as a percentage of the wild-type AR activity ± SEM

Back to article page

Genome Biology

ISSN: 1474-760X

Contact us